THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
TAMPA, Texas
Total Received
$417.7M
Total Awards
97
State
Texas
Last Updated
Mar 20, 2026
Yearly Funding Trend
$329.8M24
$41.5M25
$46.5M26
Top 50 Awards to THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Largest individual federal awards on record for this recipient, ranked by obligated amount. Data through March 20, 2026.
| Award | Awarding Agency | Program | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_P30CA010815_075 CONSOLIDATED BASIC CANCER RESEARCH PROGRAM - PROJECT SUMMARY – OVERALL THE VISION OF THE WISTAR CANCER CENTER IS TO CONQUER CANCER THROUGH OUTSTANDING RESEARCH, EDUCATION AND PA… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | PA-90 | 2024 | $52,767,907 |
ASST_NON_P01CA114046_075 TARGETED THERAPIES IN MELANOMA - PROJECT SUMMARY - OVERALL THE CLINICAL LANDSCAPE OF MELANOMA IS EVOLVING RAPIDLY, HOWEVER, A SIGNIFICANT FRACTION OF INDIVIDUALS… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | PA-90 | 2026 | $37,068,087 |
ASST_NON_UM1AI164570_075 BEAT-HIV: DELANEY COLLABORATORY TO CURE HIV-1 INFECTION BY COMBINATION IMMUNOTHERAPY - SUMMARY CURRENT HIV CURATIVE STRATEGIES HAVE PROVEN INSUFFICIENT TO ERADICATE VIRAL RESERVOI… | Department of Health and Human Services National Institutes of Health | 93.279 DRUG USE AND ADDICTION RESEARCH PROGRAMS | PHILADELPHIA, PA-03 | 2024 | $29,083,069 |
ASST_NON_UM1AI126620_075 BEAT-HIV: DELANEY COLLABORATORY TO CURE HIV-1 INFECTION BY COMBINATION IMMUNOTHERAPY - PROJECT SUMMARY THE ABSENCE OF A CURE FOR HIV-1 AFTER ANTIRETROVIRAL THERAPY IMPARTS MUL… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2024 | $23,554,270 |
ASST_NON_U19AI166916_075 SYNTHETIC DNA-LAUNCHED AND ADJUVANTED ENV IMMUNOGENS FOR HIV - OVERALL SUMMARY A PROTECTIVE VACCINE FOR HIV IS ARGUABLY THE MOST IMPORTANT PREVENTION STRATEGY TO END THE GLOBAL HI… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PHILADELPHIA, PA-03 | 2024 | $17,662,280 |
ASST_NON_U19AI109646_075 SYNTHETIC DNA & NOVEL ENV VACCINE FOR HIV - DESCRIPTION (PROVIDED BY APPLICANT): THE GOAL OF THIS PROGRAM TO PRODUCE AN ENHANCED E/P DELIVERED GENE ADJUVANTED DNA VACCINE (E-… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PHILADELPHIA, PA-03 | 2024 | $16,653,616 |
ASST_NON_U54CA224070_075 RATIONAL APPROACHES TO MELANOMA THERAPY - PROJECT SUMMARY – OVERALL THE OVERARCHING GOAL OF THIS PATIENT DERIVED XENOGRAFT (PDX) DEVELOPMENT AND TRIAL CENTER (T-PDTC) IS TO DEVELO… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | PA-90 | 2024 | $11,354,395 |
ASST_NON_P50CA261608_075 SPORE IN SKIN CANCER - PROJECT SUMMARY – OVERALL THIS WISTAR/UPENN SKIN SPORE REPRESENTS A HIGHLY SUCCESSFUL AND LONGSTANDING COLLABORATION. IMMUNE CHECKPOINT INHIBITION HAS REVOL… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | PA-90 | 2024 | $11,313,382 |
ASST_NON_T32CA009171_075 TRAINING PROGRAM IN BASIC CANCER RESEARCH - PROJECT SUMMARY THE OVERARCHING GOAL OF THIS LONGSTANDING “TRAINING PROGRAM IN BASIC CANCER RESEARCH” IS TO PROVIDE THE FUNDAMENTAL SKI… | Department of Health and Human Services National Institutes of Health | 93.398 CANCER RESEARCH MANPOWER | PHILADELPHIA, PA-03 | 2024 | $10,736,931 |
ASST_NON_R01DA048728_075 EFFECTS OF MU-OPIATE RECEPTOR ENGAGEMENT ON MICROBIAL TRANSLOCATION AND RESIDUAL IMMUNE ACTIVATION IN HIV-INFECTED, ART SUPPRESSED OPIOID USE DISORDER PATENTS INITIATING MEDICATIO… | Department of Health and Human Services National Institutes of Health | 93.279 DRUG USE AND ADDICTION RESEARCH PROGRAMS | PA-90 | 2026 | $8,373,891 |
ASST_NON_R35CA220446_075 TUMOR PLASTICITY - PROJECT SUMMARY DESPITE HALF A CENTURY OF SOCIAL AND ECONOMIC INVESTMENTS, AN UNPRECEDENTED UNDERSTANDING OF CANCER GENES AND THEIR PATHWAYS, AND AN ARSENAL O… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PA-90 | 2025 | $7,658,575 |
ASST_NON_P01CA269043_075 TARGETING THE EPIGENETIC AND METABOLIC CONTROL OF EBV-EPITHELIAL CANCERS - OVERALL – PROJECT SUMMARY THE OVERALL AIM OF THIS NEW PROGRAM PROJECT (P01) PROPOSAL IS TO GENERATE HIGH… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PHILADELPHIA, PA-03 | 2024 | $7,143,256 |
ASST_NON_R01GM084089_075 REGULATION OF ALTERNATIVE CLEAVAGE AND POLYADENYLATION - PROJECT SUMMARY MOST MAMMALIAN GENES HARBOR MULTIPLE CLEAVAGE AND POLYADENYLATION SITES, OR PASS, RESULTING IN MRNA ISOFOR… | Department of Health and Human Services National Institutes of Health | 93.859 BIOMEDICAL RESEARCH AND RESEARCH TRAINING | PA-90 | 2024 | $6,538,725 |
ASST_NON_R01GM040536_075 REGULATION OF R-LOOP FORMATION AND GENOME STABILITY BY ADAR1 - PROJECT SUMMARY ADAR (ADENOSINE DEAMINASE ACTING ON RNA) CONVERTS ADENOSINE RESIDUES TO INOSINE (A-TO-I RNA EDITING… | Department of Health and Human Services National Institutes of Health | 93.859 BIOMEDICAL RESEARCH AND RESEARCH TRAINING | PHILADELPHIA, PA-03 | 2024 | $6,301,485 |
ASST_NON_R01CA102184_075 FUNCTIONAL ANALYSIS OF P53 POLYMORPHIC VARIANTS - PROJECT SUMMARY THIS REVISED RENEWAL APPLICATION REQUESTS FUNDING FOR YEARS 15-19 FOR A PROPOSAL THAT IS DEVOTED TO UNDERSTANDING… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PA-90 | 2024 | $6,005,585 |
ASST_NON_R01DE017336_075 EPIGENETIC REGULATION OF EPSTEIN-BARR VIRUS - THE LONG-TERM GOAL OF THIS R01 IS TO UNDERSTAND HOW EPIGENETIC MECHANISMS CONTROL EPSTEIN-BARR VIRUS (EBV) LATENCY AND CARCINOGENESIS… | Department of Health and Human Services National Institutes of Health | 93.121 ORAL DISEASES AND DISORDERS RESEARCH | PHILADELPHIA, PA-03 | 2024 | $5,975,636 |
ASST_NON_R01CA140652_075 ROLE OF TERRA IN TELOMERE MAINTENANCE AND TELOMERE STRESS RESPONSE - PROJECT SUMMARY HUMAN TELOMERES ARE SPECIALIZED CHROMATIN STRUCTURES UNIQUELY PROGRAMMED TO COORDINATE CELLULA… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | PA-90 | 2024 | $5,972,986 |
ASST_NON_R01CA140964_075 AUTOPHAGY-MEDIATED DEFENSE AGAINST INFLAMMATION AND CANCER - PROJECT SUMMARY MOUNTING EVIDENCE FROM OUR LABORATORY AND OTHERS SUGGESTS THAT A LYSOSOMAL DEGRADATION PATHWAY, CALLED… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PHILADELPHIA, PA-03 | 2024 | $5,360,897 |
ASST_NON_R01CA117830_075 EPIGENOMIC CONTROL OF KSHV LATENCY - ABSTRACT: KAPOSI’S SARCOMA (KS)-ASSOCIATED HERPESVIRUS (KSHV) IS A HUMAN G-HERPESVIRUS RESPONSIBLE FOR KS, PLEURAL EFFUSION LYMPHOMA (PEL), MU… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PHILADELPHIA, PA-03 | 2024 | $5,355,138 |
ASST_NON_R01CA093606_075 REGULATION OF EBV LATENCY BY EBNA1 - EPSTEIN-BARR VIRUS (EBV) ESTABLISHES LONG-TERM LATENT INFECTIONS THAT CAN DRIVE FORMATION OF DIVERSE LYMPHOMAS AND CARCINOMAS. EBV-ASSOCIAT… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PHILADELPHIA, PA-03 | 2024 | $4,985,175 |
ASST_NON_R01AI141236_075 NOVEL DNA ENCODED MONOCLONAL ANTIBODIES (DMABS) FOR CONTROL OF ANTIMICROBIAL RESISTANT (AMR) PSEUDOMONAS AERUGINOSA INFECTION - PROJECT SUMMARY THE CONTROL OF HIGHLY ANTIMICROBIA… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2024 | $4,624,553 |
ASST_NON_R01DK123733_075 GLYCOMIC MODULATION OF GUT MICROBIOME DURING HIV INFECTION - PROJECT SUMMARY: AN EMERGING PARADIGM SUGGESTS THAT GUT GLYCOSYLATION IS A KEY FORCE IN MAINTAINING A HOMEOSTATIC RELA… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | PA-90 | 2024 | $4,535,015 |
ASST_NON_R01DA049666_075 EFFECTS OF MU-OPIATE RECEPTOR ENGAGEMENT ON THE PERSISTENCE OF HIV-ASSOCIATED ACTIVATION AND VIRAL RESERVOIRS IN INDIVIDUALS RECEIVING MEDICATION ASSISTED TREATMENT FOR OPIOID USE… | Department of Health and Human Services National Institutes of Health | 93.279 DRUG USE AND ADDICTION RESEARCH PROGRAMS | PA-90 | 2025 | $4,203,006 |
ASST_NON_U01CA200495_075 INTEGRATION OF BIOMARKER SIGNATURES FROM PERIPHERAL BLOOD FOR DIAGNOSIS, PROGNOSIS, REMISSION AND RECURRENCE OF LUNG CANCER - DESCRIPTION (PROVIDED BY APPLICANT): THE NATIONA… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | PHILADELPHIA, PA-03 | 2024 | $3,950,049 |
ASST_NON_R01CA165065_075 LIPIDS AND MYELOID CELL FUNCTION IN CANCER - PROJECT SUMMARY MYELOID CELLS ARE CRITICAL COMPONENT OF TUMOR MICROENVIRONMENT. UNDER PHYSIOLOGICAL CONDITIONS THESE CELLS ARE COMPRIS… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PA-90 | 2025 | $3,789,518 |
ASST_NON_R01AI172627_075 INVESTIGATION INTO THE ACTIVATION OF MULTIPLE BNAB PRECURSORS USING STRUCTURE-DESIGNED IMMUNOGENS AND IG KNOCK-IN MICE - PROJECT SUMMARY HIV-1 VACCINES THAT CAN ELICIT BROADLY NEU… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PHILADELPHIA, PA-03 | 2024 | $3,642,024 |
ASST_NON_UM1AI191272_075 INDIVIDUALIZED HIV CURATIVE COMBINATION STRATEGY AGAINST PERSISTENT HIV ON ART - SUMMARY WE HAVE DEMONSTRATED MULTIPLE LINES OF EVIDENCE SUPPORTING THE ROLE FOR AUTOLOGOUS NEUTRAL… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2025 | $3,568,644 |
ASST_NON_P01AI165066_075 STRUCTURAL VACCINOLOGY GUIDED DEVELOPMENT OF A UNIVERSAL COV VACCINE UTILIZING NUCLEIC ACID DELIVERED NANOPARTICLES - PROJECT SUMMARY IN DECEMBER 2019 A NOVEL CORONAVIRUS, NAMED S… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2025 | $3,517,692 |
ASST_NON_R01NS117458_075 HOST GLYCOMIC MODULATION OF HIV-ASSOCIATED NEURO-INFLAMMATION DURING VIRAL SUPPRESSION - PROJECT SUMMARY: DESPITE THE WIDESPREAD USE OF ANTIRETROVIRAL THERAPY (ART), THE PREVALENC… | Department of Health and Human Services National Institutes of Health | 93.853 EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS | PA-90 | 2025 | $3,442,219 |
ASST_NON_R01CA266342_075 THERAPEUTIC TARGETING MDSC-MEDIATED IMMUNE SUPPRESSION IN CANCER - PROJECT SUMMARY THE PROMINENT CHANGE IN THE MYELOID COMPARTMENT IN CANCER IS THE EXPANSION OF PATHOLOGICALLY ACT… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PHILADELPHIA, PA-03 | 2024 | $3,382,023 |
ASST_NON_R01CA259171_075 DRUGGING EBNA1 TO TREAT EBV-ASSOCIATED CANCERS - PROJECT SUMMARY EBV LATENT INFECTION IS RESPONSIBLE FOR ~200,000 NEW CANCERS PER YEAR. TO DATE, THERE ARE NO EBV- SPECIFIC THERAPE… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | PHILADELPHIA, PA-03 | 2024 | $3,259,551 |
ASST_NON_R01AI130209_075 REGULATION OF VIRAL CHROMATIN ARCHITECTURE DURING EBV LATENCY - EPIGENETICS IS CRUCIAL FOR REGULATING THE EPSTEIN BARR VIRUS (EBV) DIFFERENT LATENT GENE EXPRESSION PROGRAMS, REFER… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2024 | $3,249,203 |
ASST_NON_R01AI135723_075 MULTIVALENT DNA VACCINE-MEDIATED PROTECTION AGAINST TUBERCULOSIS - AN EFFECTIVE TB VACCINE REMAINS AN ELUSIVE GOAL. THE SUCCESS OF BCG IN PREVENTING DISSEMINATED TB SUGGESTS THAT… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2024 | $3,225,285 |
ASST_NON_R01AI165079_075 TARGETING SIGLEC-9/SIALOGLYCAN INTERACTIONS TO ENHANCE NK FUNCTIONS DURING HIV INFECTION - PROJECT SUMMARY: THE FUNCTIONS OF NATURAL KILLER (NK) CELLS CAN BE INFLUENCED BY THE CEL… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | IL-90 | 2024 | $3,144,475 |
ASST_NON_R01DK124385_075 ROLE OF THE P53 P47S MUTATION IN INFLUENCING PREVALENCE AND IMMUNE RESPONSE TO H. PYLORI - WE DISCOVERED THAT A HUMAN TP53 GENE VARIANT AT AMINO ACID 47 CODES FOR A “HYPOMORPHIC”… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | PA-90 | 2024 | $3,013,399 |
ASST_NON_R01AG062383_075 SIALIC ACID MODULATION OF HIV-ASSOCIATED CHRONIC INFLAMMAGING - PROJECT SUMMARY: AN HIV-ASSOCIATED STATE OF CHRONIC INFLAMMATION PERSISTS DESPITE ANTIRETROVIRAL THERAPY (ART) AND… | Department of Health and Human Services National Institutes of Health | 93.866 AGING RESEARCH | PA-90 | 2024 | $3,005,725 |
ASST_NON_R01ES029092_075 MOLECULAR MECHANISM OF UV PROTECTION IN CUTANEOUS MELANOMA - PROJECT SUMMARY ULTRAVIOLET RADIATION (UVR) FROM SUNLIGHT HAS BEEN EPIDEMIOLOGICALLY IDENTIFIED AS A LEADING RISK FACT… | Department of Health and Human Services National Institutes of Health | 93.113 ENVIRONMENTAL HEALTH | PA-90 | 2025 | $2,981,851 |
ASST_NON_R01CA238457_075 A CANCER-DERIVED TRUNCATING MUTATION IN DISEASE PENETRANCE AND PROGRESSION OF MSI CRC - PROJECT SUMMARY COLORECTAL CANCER (CRC) RANKS AS THE 2ND MOST COMMON CAUSE OF CANCER MORTAL… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | PHILADELPHIA, PA-03 | 2024 | $2,838,641 |
ASST_NON_R01HL141326_075 ROLE OF AN INTEGRATOR-EGR AXIS IN THE REGULATION OF MYELOID ENHANCERS - PROJECT SUMMARY ROLE OF AN INTEGRATOR-EGR AXIS IN THE REGULATION OF MYELOID ENHANCERS OBJECTIVE: MY RESEARC… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | PA-90 | 2025 | $2,726,822 |
ASST_NON_DP2AI175470_075 MANIPULATING EPITOPE IMMUNODOMINANCE AND TRACKING B-CELL-ANTIGEN INTERACTIONS FOR VACCINE DESIGN. - PROJECT SUMMARY/ ABSTRACT INFECTIOUS DISEASES ARE SERIOUS AND RECURRENT HEALTH… | Department of Health and Human Services National Institutes of Health | 93.310 TRANS-NIH RESEARCH SUPPORT | PA-90 | 2025 | $2,721,210 |
ASST_NON_DP2CA249950_075 THE MULTIFACETED ROLE OF ACETATE IN CANCER - PROJECT SUMMARY STUDIES ARE SHOWING THAT MORE AMERICANS ARE DRINKING ALCOHOL, AND PROBLEMATIC HIGH-RISK DRINKING IS PARTICULARLY ON TH… | Department of Health and Human Services National Institutes of Health | 93.310 TRANS-NIH RESEARCH SUPPORT | PHILADELPHIA, PA-03 | 2024 | $2,671,932 |
ASST_NON_R01HL147472_075 REGULATION OF NEONATAL INFLAMMATION BY MYELOID-DERIVED SUPPRESSOR CELLS - PROJECT SUMMARY OVER ONE QUARTER OF EXTREMELY PRETERM INFANTS DIE DURING THE FIRST MONTHS OF LIFE. DYSREG… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | PA-90 | 2025 | $2,518,959 |
ASST_NON_R01CA216936_075 NEGATIVE REGULATION OF MYELOID-DERIVED SUPPRESSIVE CELLS IN CANCER - MYELOID CELLS ARE CRITICAL COMPONENT OF TUMOR MICROENVIRONMENT. ABNORMAL DIFFERENTIATION OF MYELOID CELLS IS N… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PHILADELPHIA, PA-03 | 2024 | $2,494,012 |
ASST_NON_R01CA215733_075 TARGETING TERT IN MELANOMA - PROJECT SUMMARY MELANOMA IS A DEVASTATING DISEASE, WITH FIVE-YEAR SURVIVAL RATES FOR METASTATIC DISEASE UNDER 15%. EXCITING NEW THERAPIES HAVE EM… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | PHILADELPHIA, PA-03 | 2024 | $2,445,218 |
ASST_NON_R01CA268510_075 TARGETING S6K2 TO OVERCOME DRUG RESISTANCE IN NRAS-MUTANT MELANOMA - PROJECT SUMMARY WHILE SEVERAL THERAPIES HAVE BEEN APPROVED FOR MELANOMA, THERE ARE LIMITED TREATMENT OPTIONS… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | PA-90 | 2024 | $2,440,545 |
ASST_NON_R01AI153508_075 REGULATION OF EBV LATENCY BY PURINE METABOLISM AND SIGNALING - EPSTEIN-BARR VIRUS (EBV) REPROGRAMS HOST CELL GENE EXPRESSION AND METABOLISM DURING THE ESTABLISHMENT OF LATENCY AND… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PHILADELPHIA, PA-03 | 2024 | $2,287,875 |
ASST_NON_R01CA238611_075 THE IMPACT OF CODING REGION VARIANTS ON MUTANT P53 BIOLOGY - PROJECT SUMMARY IT IS NOW WELL ACCEPTED THAT TUMOR-DERIVED MUTANT FORMS OF P53 ARE POTENTLY ONCOGENIC. SILENCING MU… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PHILADELPHIA, PA-03 | 2024 | $2,223,406 |
ASST_NON_R01CA272645_075 DESIGN OF THE FIRST MDM2 TARGETING PROTACS FOR TREATMENT OF P53 MUTANT OR DEFICIENT CANCERS - PROJECT SUMMARY / ABSTRACT OUR PROPOSAL FOCUSES ON THE DEVELOPMENT OF NOVEL MDM2-TARG… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | PHILADELPHIA, PA-03 | 2024 | $2,147,095 |
ASST_NON_R01NS127828_075 CTCF-DEPENDENT MECHANISMS OF ATRX IN NEURONAL DIFFERENTIATION - PROJECT SUMMARY ATRX IS AN EPIGENETIC FACTOR THAT IS MUTATED IN ATRX SYNDROME. ATRX IS REQUIRED FOR THE MAINTENANCE… | Department of Health and Human Services National Institutes of Health | 93.853 EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS | PHILADELPHIA, PA-03 | 2024 | $2,106,664 |
ASST_NON_R01CA262631_075 NEW CONTROL OF ONCOGENE ACTIVATION IN T-CELL LEUKEMIA - PROJECT SUMMARY/ABSTRACT NOTCH1 SIGNALING IS AN IMPORTANT MEDIATOR OF STEM CELL SELF-RENEWAL AND THERAPEUTIC RESISTANCE, AN… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | PHILADELPHIA, PA-03 | 2024 | $2,064,320 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Federal Programs (CFDA)
View All→12345678910
93.855 — ALLERGY AND INFECTIOUS DISEASES RESEARCH$90.3M
93.397 — CANCER CENTERS SUPPORT GRANTS$75.4M
93.396 — CANCER BIOLOGY RESEARCH$63.9M
93.395 — CANCER TREATMENT RESEARCH$52.1M
93.279 — DRUG USE AND ADDICTION RESEARCH PROGRAMS$41.7M
93.859 — BIOMEDICAL RESEARCH AND RESEARCH TRAINING$21.6M
93.398 — CANCER RESEARCH MANPOWER$10.7M
93.393 — CANCER CAUSE AND PREVENTION RESEARCH$9.3M
93.853 — EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS$8.2M
93.847 — DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH$7.5M
Source: USAspending.gov · All Recipients · Texas